A Phase 1, Double-Blind, Ra ndomized, Placebo -Controlled, 
Single -Dose Intravenous Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of IXT-m200 in Healthy 
Participant s 
Protocol Number: M200C-2102 
IND Sponsor: InterveXion Therapeutics , LLC 
Funded by: NIH/NIDA U01 DA045366 
Version Number:  1 
25 Aug 2021 
[STUDY_ID_REMOVED]
  
 ii TABLE OF CONTENTS  
 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  ii 
SPONSOR APPROVAL AND SIGNATURE PAGE  ................................ ................................ .... 1 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  2 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ........  3 
1.1 Synopsis  ................................ ................................ ................................ ...........................  3 
1.2 Schema  ................................ ................................ ................................ .............................  4 
1.3 Schedule of Activiti es ................................ ................................ ................................ ...... 5 
2 INTRODUCTION  ................................ ................................ ................................ ....................  6 
2.1 Background  ................................ ................................ ................................ ......................  6 
2.1.1  Study Agent  ................................ ................................ ................................ ........  6 
2.1.2  Nonclinical IXT -m200 Effectiveness Summary  ................................ ................  6 
2.1.3  Nonclinical Safety  Summary of IXT -m200  ................................ .......................  6 
2.1.4  Clinical Research Summary  ................................ ................................ ...............  6 
2.2 Risk/Benefit Assessment  ................................ ................................ ................................ . 7 
2.2.1  Known Potential Risks  ................................ ................................ .......................  7 
2.2.2  Known Potential Benefits  ................................ ................................ ..................  8 
2.2.3  Assessment of Potential Risks and Benefits  ................................ ......................  8 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ..........................  9 
4 STUDY DESIGN ................................ ................................ ................................ ......................  9 
4.1 Overall Design  ................................ ................................ ................................ .................  9 
4.2 Justification for Dose  ................................ ................................ ................................ ....... 9 
4.3 End of Study Definition  ................................ ................................ ................................ ... 9 
5 STUDY POPULATION  ................................ ................................ ................................ .........  10 
5.1 Inclusion Criteria  ................................ ................................ ................................ ...........  10 
5.2 Exclus ion Criteria  ................................ ................................ ................................ ..........  10 
5.3 Rationale for the Selected Population  ................................ ................................ ............  11 
5.4 Lifestyle Considerations  ................................ ................................ ................................  11 
5.5 Screen Failures  ................................ ................................ ................................ ...............  11 
5.6 Strategies for Recruitment and Retention  ................................ ................................ ...... 11 
6 STUDY INTERVENTION  ................................ ................................ ................................ ..... 12 
6.1 Study Intervention(s) Administration  ................................ ................................ ............  12 
6.1.1  Study Intervention Description  ................................ ................................ ........  12 
6.1.2  Dosing and Administration  ................................ ................................ ..............  12 
6.2 Preparation/Handling/Storage/Accountability  ................................ ...............................  12 
6.2.1  Acquisition and accountability  ................................ ................................ .........  12 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................ ....... 12 
6.2.3  Product Storage and Stability  ................................ ................................ ...........  13 
6.2.4  Preparation  ................................ ................................ ................................ ....... 13 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........  13 
6.4 Study Intervention Compliance  ................................ ................................ .....................  14 
6.5 Concomitant Therapy  ................................ ................................ ................................ .... 14 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ................................ ................................ ...............  14 
7.1 Discontinuation of Study Intervention  ................................ ................................ ...........  14 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............  14 
  
 iii 7.3 Lost to Follow -Up ................................ ................................ ................................ ..........  15 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .. 15 
8.1 Safety and Other Assessments  ................................ ................................ .......................  15 
8.1.1  Eligibility Criteria  ................................ ................................ ............................  15 
8.1.2  Medical and Medication History  ................................ ................................ ...... 16 
8.1.3  Vital Signs  ................................ ................................ ................................ ........  16 
8.1.4  Physical Exam  ................................ ................................ ................................ .. 16 
8.1.5  Psychiat ric Evaluation  ................................ ................................ ......................  16 
8.1.6  Pregnancy Test  ................................ ................................ ................................ . 16 
8.1.7  Laboratory Tests  ................................ ................................ ..............................  16 
8.1.8  Electrocardiograms  ................................ ................................ ..........................  17 
8.1.9  Blood for PK/HACA and Cytokines  ................................ ................................  17 
8.2 Adverse Events and Serious Adverse Events  ................................ ................................  17 
8.2.1  Definition of Adverse Events (AE)  ................................ ................................ .. 17 
8.2.2  Definition of Serious Adverse Events (SAE)  ................................ ..................  18 
8.2.3  Classification of an Adverse Event  ................................ ................................ .. 18 
8.2.4  Time Period and Frequency for Event Assessment and Follow -Up ................  19 
8.2.5  Adverse Event Reporting  ................................ ................................ .................  20 
8.2.6 Serious Adverse Event Reporting  ................................ ................................ .... 20 
8.2.7  Reporting Events to Participants  ................................ ................................ ...... 21 
8.2.8  Events of Special Interest  ................................ ................................ .................  21 
8.2.9  Reporting of Pregnancy  ................................ ................................ ...................  21 
8.3 Unanticipated Problems  ................................ ................................ ................................ . 21 
8.3.1  Definition of Unanticipated Problems (UP)  ................................ .....................  21 
8.3.2  Unanticipated Problem Reporting  ................................ ................................ .... 21 
8.3.3  Reporting Unanticipated Problems to Participants  ................................ ..........  22 
9 STATISTICAL CONSIDERATIONS ................................ ................................ ....................  22 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .... 22 
9.2 Sample Size Determination  ................................ ................................ ...........................  22 
9.3 Populations for Analyses  ................................ ................................ ...............................  23 
9.4 Statistical Analyses  ................................ ................................ ................................ ........  23 
9.4.1  General Approach  ................................ ................................ ............................  23 
9.4.2  Safety Analyses  ................................ ................................ ................................  23 
9.4.3  Baseli ne Descriptive Statistics  ................................ ................................ .........  23 
9.4.4  Tabulation of Individual participant Data  ................................ ........................  23 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .........  24 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ............  24 
10.1.1  Informed Consent Process  ................................ ................................ ...............  24 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .. 24 
10.1.3  Confidentiality and Privacy  ................................ ................................ .............  25 
10.1.4  Future Use of Stored Specimens and Data  ................................ .......................  25 
10.1.5  Key Roles and Study Governance  ................................ ................................ ... 26 
10.1.6  Safety Oversight  ................................ ................................ ...............................  26 
10.1.7  Clinical Monitoring  ................................ ................................ ..........................  26 
10.1.8  Quality Assurance and Quality Control  ................................ ...........................  26 
10.1.9  Data Handling and Record Keeping  ................................ ................................  27 
10.1.10  Protocol Deviations  ................................ ................................ ..........................  28 
  
 iv 10.1.11  Publication and Data Sharing Policy  ................................ ...............................  28 
10.1.12  Conflict of Interest Policy  ................................ ................................ ................  28 
10.2  Abbreviations  ................................ ................................ ................................ .................  29 
10.3  Protocol Amendment History  ................................ ................................ ........................  30 
11 REFERENCES  ................................ ................................ ................................ .......................  31 
 
Phase I Safety, Tolerability, and Pharmacokinetics oflXT-m200 in Healthy Volunteers 
M200C-2102 
Sl'O\SOR Al'l'RO\'AL A\D SIG\:\ n11u: PAGE 
Chief Medical Officer 
Chief Operating Officer Version I 
25 Aug2021 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   2 STATEMENT OF COMPLIANCE  
 
The trial will be conducted in accordance with International Conference on Harmonisation Good Clinical 
Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and the National 
Institute on Drug Abuse (NIDA) Terms and Conditions  of Award. The Investigator will assure that no 
deviation from, or changes to the protocol will take place without prior agreement from InterveXion 
Therapeutics and documented approval from the Institutional Review Board (IRB), except where 
necessary to el iminate an immediate hazard(s) to the trial participants. All personnel involved in the 
conduct of this study have completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant  materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form must 
be obtained before any participant is enrolled. Any amendment to the protocol will require review and 
approval by the IRB before the ch anges are implemented to the study. All changes to the consent form 
will be IRB approved; a determination will be made regarding whether a new consent needs to be 
obtained from participants who provided consent using a previously approved consent form.  
 
 
 
 
Investigator Signature/Date: _____________________________________________________________   
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   3 1 PROTOCOL SUMMARY  
 
1.1 SYNOPSIS  
Title:  A Phase 1, Double -Blind, Randomized, Placebo -Controlled, Single -Dose 
Intravenous Study to Evaluate the Safety and Pharmacokinetics of IXT -
m200 in Healthy Participants  
Study Description:  This Phase 1 study will evaluate the safety and pharmacokinetics  of a single 
3-g dose of IXT -m200 given by intravenous in fusion  to healthy 
participants.  
Objectives:  
 Primary Objectiv e: To evaluate the safety and tolerability of a single 3-g 
intravenous dose of IXT -m200 in healthy participants via physical 
examinations and adverse event, vital sign, ECG, and clinical laboratory 
testing.  
 Secondary Objectives: To characterize the pharmacokinetics of IXT -m200 
following a single  3-g intravenous dose of IXT -m200 in healthy 
participants by measurement of IXT -m200 concentrations.  
Endpoints:  Primary Endpoint:   
• Number of participants with treatment -related AEs assessed by 
physical examinations and vital sign, AE, ECG, and clinical 
laboratory testing.  
Secondary Endpoints:  
• Time course of IXT -m200 concentrations  
Study Population:  Approximately 9 healthy  adults will be randomized into the study.  
Phase:  1 
Description of Sites:  Approximately 1 site in the US will enroll participants  
Description of Study 
Intervention:  IXT-m200 is a high -affinity chimeric anti -METH monoclonal antibody that 
is well -tolerated in healthy volunteers and in non -intoxicated participants  
with METH use disorder  when administered up to 20 mg/kg 
(approximately 1.5 g) . It will be administered at a dose of 3 g 
(approximately 40 mg/kg)  in this study.  IXT-m200 or  placebo treatment 
will be given by intravenous infusion over 30 minutes .  
Study Duration:  Approximately 5 months  
Participant Duration:  18 weeks  
  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   4 1.2 SCHEMA  
 
 
  
Screening Visit
Day -30 to -1
Inpatient
Days 1 and 2
Subject 
participation 
concluded•Laboratory tests and wellness check
•ECG and pregnancy test
•Blood samples for cytokines, PK, and HACA
•Randomization and dosing•Informed consent
•Initial evaluations
•Laboratory tests
Follow-up 
Days 8, 15, 22, 29, 
36, 43, 64, 85, & 106•Laboratory tests (Days 8, 28, and 63 only)
•Wellness check 
•Blood samples for PK
Final Study Visit
Day 127•Wellness check 
•Pregnancy test
•Blood samples for PK and HACA
Follow for AEs
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   5 1.3 SCHEDULE OF ACTIVITIES  
 
Assessment a Screening  Inpatient  Follow -up (±1 day)  Follow -up (±3 days)  ET 
Study Week  ≤-1 1 2 3-17 18 NA 
Study Day  -30 to -1 1b 2 8 15, 22, 29, 36, 43, 
64, 85, 106  127 NA 
Informed consent  X       
Initial evaluations  
Eligibility criteria  
Demographics  
Medical history and 
medications  
Vital signs c  
Physical exam  
Psychiatric evaluation  
Urine pregnancy test  X       
Laboratory tests d X X X X X (29 and 64 only)   X 
Urine drug screen   X      
Wellness check  
Update medical history  
Update medications  
Vital signs c 
Targeted physical exam   
X X X X X X 
ECG e  X      
Urine pregnancy test  X    X X 
Blood for cytokines f  X      
Blood for PK g   X X X X X X 
Blood for HACA h  X    X X 
Randomization   X      
Dose administration i  X      
AE monitorin g  Continuous  X 
Abbreviations: ECG – electrocardiogram; ET – early termination  visit; HACA – human anti -chimeric antibodies; 
NA – not applicable; PK – pharmacokinetic  
 
a Descriptions of assessments are in Section 8.1. 
b Study Day -1 is the day prior to the first dose. Study Day 1 is the day of the first dose.  
c Vital sign measurements will be taken on Day 1  starting with a pre -dose measurement (≤30 min pri or), then 0.25, 
0.5, 1, 2, and 4 hours (±5 min) after dosing starts, and as needed afterward until normalization. Measurements will 
be obtained once on each non -dosing day. Each test may be repeated once at each time point if the initial result is 
out of r ange.  
d Laboratory tests require blood and urine sampling for hematology, serum chemistry, and urinalysis. Samples are to 
be taken  at screening, pre -dose and  2-hr post -dose completion  (±10 min) on Day 1 , and once on Days 2, 8, 29, and 
64. 
e ECGs are to be done pre-dose (up to 2 hr prior) and 30-min post -dose completion (±15 min) on Day 1 .   
f Cytokine samples are to be taken pre -dose (≤60 min prior) on Day 1. If a participant has an infusion reaction, 
cytokine sampling at 1 - and 4-hours post -dose (±10 min) should be performed. If no infusion reaction is observed, 
pre-dose samples will not be analyzed.  
g PK samples are to be taken pre -dose (≤30 min prior ), then 1, 4, and 8 hr (±10 min)  and 24 hr (±30 min) after the 
start of the infusion on Day 1 . All other PK samples are to be collected once each visit.  
h HACA samples are to be taken pre -dose (≤60 min prior) on Day 1  and once on Day 126 .  
i Doses will be given over 30 min by IV infusion.   
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   6 2 INTRODUCTION  
 
2.1 BACKGROUND   
 
2.1.1  STUDY AGENT  
 
IXT-m200, also called ch -mAb7F9, binds METH with high selectivity and affinity. The product contains 
a murine METH -binding variable region and the constant domains of a human immunoglobulin G 
(IgG)  2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an 
IgG 1 or IgG 3. IXT -m200 targets METH, does not rely on binding to any endogenous target for its action, 
and has been well -tolerated in previous clinical studies (see below).  
  
Through the binding of METH i n the bloodstream, it is anticipated that IXT -m200 will alter the 
pharmacokinetics (PK)  of METH and decrease concentrations of METH reaching its active sites in the 
brain. The presence of IXT -m200 should therefore decrease the perceived pleasurable effects  of METH. 
Over the longer term, when combined with behavior al therapy, IXT -m200 should reduce the frequency of 
METH use over time.  
  
2.1.2  NONCLINICAL IXT -M200 EFFECTIVENESS SUMMARY  
 
A significant body of nonclinical work in rats indicates that IXT -m200 may be e ffective as a treatment for 
METH use disorders by altering METH CNS effects. The potential human efficacy of IXT -m200 is 
demonstrated by  multiple  in vivo  preclinical studies using the murine version of the antibody, called 
mAb7F9. The studies and results a re summarized in the Investigator’s Brochure  (IB). 
 
2.1.3  NONCLINICAL SAFETY SUMMARY OF IXT -M200  
 
InterveXion has performed multiple nonclinical safety studies with IXT -m200 which support dosing in 
humans, and the results of these studies are summarized in the IB. Briefly, a single -dose GLP toxicology 
study was performed  in rats at doses up to 400 mg/k g. No test article -related  mortality or evidence of 
systemic toxicity was observed and no target organs were identified  (No Observed Adverse Effect Level 
(NOAEL ) > 400 mg/kg). High titers of anti -IXT-m200 antibodies were detected in the serum of 1  rat each  
dosed at 50 mg/kg, 150 mg/kg, and 400 mg/kg.  Furthermore, a  repeat -dose GLP toxicology study was 
performed in rats using weekly dosing at doses up to 300 mg/kg/week for 26 weeks. No test-article 
related mortality or evidence of systemic toxicity was obse rved and no target organs were identified 
(NOAEL > 300 mg/kg). No animals in this study were confirmed positive for anti -IXT-m200 antibodies.  
 
Additional nonclinical safety studies have also been performed in combination with METH to evaluate 
the potential  interaction of IXT -m200 and METH. Results from these studies are also summarized in the 
IB, and there were no adverse effects, as measured by cardiovascular parameters or body 
temperature/activity, attributed to IXT -m200 administration when followed by hi gh doses of METH.  
 
2.1.4  CLINICAL RESEARCH SUMMARY  
 
A Phase 1 study of the safety of single doses of IXT -m200 in healthy humans has been completed1. In this 
first clinical study, 42 participants  (17 females) were dosed in 5 groups (0.2, 0.6, 2, 6, or 20 mg/kg 
IXT-m200), with 10 participants receiving placebo (saline). Pharmacokinetic results indicate d that 
IXT-m200 is similar to other IgGs, with an elimination half -life of ~18 days, volume of dis tribution (V d) 
of ~5  L and clearance of ~200 mL/d. The disposition of IXT -m200 d id not appear to be affected by dose.  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   7   
There were no serious adverse events (SAEs) or serious adverse reactions during the conduct of the study. 
There were 3 adverse events in  2 subjects that were attributed to IXT -m200. A mild infusion reaction 
(Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 Grade 3) and bronchospasm (Grade 
2) occurred in the same subject. The symptoms included a brief period of bronchospasm with  no drop in 
oxygen saturation that resolved with stopping the infusion. A separate subject experienced an AE of mild 
proteinuria (Grade 1). Both subjects were in the same dose group (2 mg/kg IXT -m200).  
  
Samples from all participants  were tested for immun ogenicity, ie, anti -IXT-m200 antibodies. Samples 
from only 4 (12.5%) IXT -m200 treated participants  were confirmed to have low titers. One of these 4 
participants  also provided a pre -dose sample that screened positive for anti -IXT-m200 antibodies. The 
devel opment of anti -IXT-m200 antibodies did not appear to be dose -related.  
  
Overall , there were no apparent safety or tolerability concerns identified when IXT -m200 was dosed over 
the range from 0.2 to 20 mg/kg. Therefore, a maximum tolerated dose was not reac hed. 
  
Following the Phase 1 study, a Phase 2 study of IXT -m200 was conducted ( STAMPOUT : Study of 
Antibody for Methamphetamine Outpatient Therapy, [STUDY_ID_REMOVED] ). This was a parallel -group, placebo -
controlled, double -blind study in otherwise healthy, non -treatment seeking participants  who use METH . 
Participants  were required to discriminate METH (30 mg, intravenous ) from placebo with a drug effects 
questionnaire (DEQ)  to qualify. Those who qualified received single doses of IXT -m200 (6 or 20 mg/kg) 
or placebo  followed by weekly METH challenges for up to 4 weeks. The challenges consisted of METH 
(30 mg, intravenous ) and placebo, separated by 4 h ours. Safety, METH and IXT -m200 PK, and DEQ data 
were collected for up to 126 days . 
 
56 participants  were included in the pharmacokinetic and safety sets, with 20 receiving the placebo, 18 
receiving 6 mg/kg  IXT-m200 , and 18 receiving 20 mg/kg IXT -m200. IXT -m200 was well -tolerated. 
There were no SAEs and all AEs were grades 1 or 2; all resolved as expecte d. Importantly, IXT -m200 did 
not result in substantial hemodynamic changes when compared with METH alone. IXT -m200 met the 
primary study endpoint, and significantly (p<0.001) altered METH AUC and Cmax with all METH 
challenges, up to 30 -fold and 8 -fold resp ectively, without altering METH renal elimination  . IXT -m200 
decreased METH Vd over 9 -fold after the first METH challenge. Though the study was not powered for 
pharmacodynamic changes, t here were favorable trends in DEQ data , suggesting  that IXT -m200 has 
favorable effects on the reinforcing effects of METH use.  This study is discussed further in the IB.  
 
2.2 RISK/BENEFIT ASSESSMENT   
 
2.2.1  KNOWN  POTENTIAL RISKS  
2.2.1.1  GENERAL MAB POTENTIAL RISKS  
 
Given that there are more than 50 Food and Drug Administration (FDA) -approved mAb medications, and 
several with non -endogenous targets that have been approved (Anthim®, Abthrax®, Synagis®, 
Zinplava®) or are in late -stage clinical trials, risks may be predicted and strategies developed to mitigate 
these risks based on an understanding of the pharmacology of these approved medications. These are 
outlined in the IB along with a summary of the nonclinical toxicology studies of IXT -m200 in absence 
and presence of high -dose METH in rats.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   8 2.2.1.2  SPECIFIC IXT -M200 POTENTIAL RISKS  
 
During the Phase 1 study of IXT -m200, there were no SAEs or discontinuations due to treatment -
emergent AEs. Overall, 90% of participants  experienced at least 1 AE, but there were no apparent trends 
in the frequency, relatedness, or severity of AEs with inc reased dose or between active - and placebo -
treated participants1. 
  
There were 3 adverse events in 2 subjects that were attributed to IXT -m200. A mild infusion reaction 
(CTCAE v.4.0 Grade 3) and bronchospasm (Grade 2) occurred in the same subject. The sy mptoms 
included a brief period of bronchospasm with no drop in oxygen saturation that resolved with stopping 
the infusion. A separate subject experienced an AE of mild proteinuria (Grade 1). Both subjects were in 
the same dose group (2 mg/kg IXT -m200).  
  
The most frequently reported AEs were increased blood creatine phosphokinase, upper respiratory tract 
infection, decreased hemoglobin, headache, increased aspartate aminotransferase (AST) and alanine 
aminotransferase  (ALT) , proteinuria, decreased white bloo d cell (WBC) count, and nasal congestion.  
  
Because IXT -m200 is a mouse -human chimeric antibody, the potential for a human anti -chimeric 
antibody (HACA) response exists. Following single doses of IXT -m200, only 4 of 32 participant s were 
confirmed positive for HACA in the Phase 1 study. The development of HACA did not appear to be dose -
relate d. 
 
In the  Phase 2a STAMPOUT study , all AEs were grade 1 or grade 2. Common AEs included palpitations, 
tachycardia, dry mouth, nausea, injection site pain, headache, eup horia, hypervigilance, and 
hyperhidrosis. All of these AEs are expected in people receiving METH, and all participants in this study 
received METH. Of these, only blurred vision, nausea , feeling abnormal,  and dry mouth were probably 
related to  IXT-m200 ; each AE was reported by only one subject  who received IXT -m200 . Furthermore, 
none of the AEs associated with METH appeared to be exacerbated by IXT -m200. For example, an 
analysis of heart rate changes following METH administration demonstrated t hat average percent heart 
rate increase, and average peak heart rates were not changed in the presence of IXT -m200. Plus, the 
individual maximum attained heart rate in each group was 139 (placebo), 142 (6 mg/kg), and 144 
(20 mg/kg).  
 
Finally, as in the Ph ase 1 study, samples from all participants were tested for HACA . Only one participant 
in each IXT -m200 dose group had notable titers of anti -IXT-m200 antibodies, and the PK of IXT -m200 
in these participants did not differ from other participants in the dos e group.  
 
2.2.2  KNOWN POTENTIAL BENEFITS  
 
IXT-m200 is an investigational product which has no pharmacologic activity beyond binding METH, and 
will convey no benefit to participants  who do not use METH .  
 
2.2.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
 
The risks of exposing the participants to IXT -m200 are justified to determine its safety at this increased 
dose level of 3 g .  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   9 3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  
Primary   
To evaluate the safety and tolerability of a single 
3-g intravenous dose of IXT -m200 in healthy 
participants.  Number of participants with treatment -related AEs 
assessed by physical examinations and vital sign, 
ECG, and clinical laboratory testing.  
Second ary  
To characterize the pharmacokinetics of IXT -
m200 following a single 3 -g intravenous dose of 
IXT-m200 in healthy participants .  Time course of IXT -m200 concentrations  
 
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
Approximately 9 participants will be enrolled in the study in a single cohort. Participants will be 
randomized to 3 g IXT -m200 or placebo at 7:2. Each will receive their dose as a 30 -min IV infusion, then 
remain at the study site overnight  to complete Day 1 and Day 2 assessments (e.g., ECG, laboratory 
assessments, blood draws, and vital signs). Following discharge on Day 2, participants will return to the 
clinic for follow -up PK and safety assessments on Day 8, then every 1-3 weeks thereafter until Day 12 7. 
 
4.2 JUSTIFICATION  FOR DO SE 
 
The IXT -m200 dose of 3 g was selected for this study because it is potentially effective in reducing 
METH effects for several weeks , and will be used in an upcoming repeat -dose Phase 2 clinical study in 
patients with METH use disorder. Prior to this  Phase 2  study, safety and pharmacokinetics of a single 3 -g 
dose in healthy volunteers will be established .  
 
IXT-m200 will be administered via IV infusion  over 30 min . This is necessary because it is a protein 
medication and would be metaboli zed to inactive components in the gastrointestinal tract if administered 
orally. The volume that must be given is too large to allow for intramuscular or subcutaneous 
administration based on the current formulation. This will result in a rate of 40 mg/kg/h r in a 75 -kg 
person,  which is significantly lower than doses given during a multiple -dose GLP toxicology study in 
which the slowest  rate for the high dose was 1800 mg/kg/hr.  
 
4.3 END OF STUDY DEFINITION  
A participant is considered to have completed the study if s/he has completed all phases of the study 
including the last visit or last scheduled procedure shown in  1.3. The end of the study is defined  as 
completion of the last visit or procedure in the trial globally.  
Participants  who have an ongoing AE at the time of study completion will be followed as described in 
8.2.5 . 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   10 5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
Eligible participants will:  
1. Be at least 18 years of age at the time of study consent ; 
2. Be able and willing to read, comprehend, and give Authorization for Use/Disclosure of Health 
Information (HIPAA) and informed consent;  
3. Be healthy, based on the pre -study medical evaluation (medical history and physical exam, vital 
signs, ECG, and clinical laboratory evaluations);  
4. Be willing to comply with  study instructions and dosing, agree to make all appointments, and 
complete the entire course of the study;  
5. Be of nonchildbearing potential or a gree to use protocol -specified method(s) of birth control 
throughout study participation;  
6. Agree to adhere to Li festyle Considerations throughout study duration  (see section 5.3). 
 
5.2 EXCLUSION CRITERIA  
 
Eligible participants will NOT:  
1. Have a history of treatment with a monoclonal antibody in the past year;  
2. Have a known contraindication or sensitivity to IXT -m200 based on known allergies to other mAbs, 
any inactive ingredient of IXT -m200, or any other products required for the study procedures ; 
3. Have a history of alcohol and/or drug use disorder , as determined by DSM -5 criteria ; 
4. Have a history of stimulant use, including methamphetamine  and amphetamine ; 
5. Be currently taking certain other drugs and medications, including: “designer drugs” (e.g., 3,4 -
methylene dioxyMETH (MDMA, Ecstasy, Adam, XTC) and its N -dimethyl metabolite  
methylenedioxyamphetamine (MDA), anti -orexigenic drugs (including over -the-counter medications 
for weight loss), or be chronic users of phenethylamine compounds (e.g., phenylpropanolamine, 
ephedrine, pseudoephedrine, amphetamine, phentermine, phenmetrazine, methylphenidate, 
diethylpropion, and propylhexedrine);  
6. Have a positive drug screen for any psychoactive substances (legal or nonlegal) on Day 1 prior to 
dosing ; 
7. Have a history of severe allergy (rash, hives, breathing difficulty, etc) to any medications ; 
8. Have a history of allergic or environmental bronchial asthma within the past 3 years ; 
9. Have a clinically significant history of or current abnormality or disease o f any organ system, 
including renal, hepatic, gastrointestinal, cardiovascular, pulmonary (including chronic asthma), 
endocrine (eg, diabetes), central nervous, or hematologic systems, or recent clinically significant 
surgery,  
10. Have a history of seizure, ep ilepsy, severe head injury, multiple sclerosis, or other known 
neurological conditions,  
11. Have a planned or scheduled surgical procedure during the study;  
12. Have recently donated blood or plasma (within 30 days of study drug dose) ; 
13. Have a current diagnosis of  anorexia nervosa or bulimia disorder ; 
14. Be currently participating or has participated within the last 30 days prior to the start of this study in a 
drug, device , or other interventional research study ; 
15. Be pregnant or lactating;  
16. In the Investigator’s or Spo nsor’s (or designee) opinion, be inappropriate for the study . 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   11  
5.3 RATIONAL E FOR THE SELECTED  POPULATION  
 
Phase 1 PK and safety studies have frequently been done in healthy subjects with many chimeric mAbs, 
including IXT -m2001. This study is designed to increase the dose level tested in healthy participants prior 
to testing in patients that use METH.  
 
5.4 LIFESTYLE CONSIDERATIONS  
 
IXT-m200 may alter the pharmacokinetics of molecules that are structurally similar to METH; therefore, 
participants should not tak e drugs such as amphetamine (including Adderall®, Dexedrine®, or Evekeo®) 
or MDMA (also known as ecstasy) for the duration of study participation.  
 
Participants are prohibited from the following during the study period:  
• Ingesting or using any other investi gational drug or device.  
• Donating blood, plasma, platelets, eggs or sperm.  
 
Participants  will be encouraged to limit their ethanol consumption to approximately 1 drink per day for 
women and 2 drinks per day for men while in the study.  
 
Participants  are req uired to practice an adequate method of birth control, including intrauterine device 
(IUD); oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; barrier methods with 
spermicide ; or vasectomized partner  throughout the study.  
 
5.5 SCREEN F AILURES  
 
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participants , to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography , screen failure details, 
eligibility criteria, and any serious adverse event (SAE).  
 
Individuals  who do not meet the criteria for participation in this trial (screen failure) because of a short 
term or temporary medical issue  may be rescreened  (≥30 days later) .  
 
5.6 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
Traditional advertising methods will be utilized to ensure recruitment goals are met. This will be 
accomplished by using advertising such as print, electronic, and/or digital newspapers, flyers , mailers, 
billboards, television, radio, online, social networking, and other means of communicating with potential 
participants  that are IRB -approved. The site subject database may also be searched to identify potential 
participants.  
  
All recruitment m aterials will refer interested persons to a contact email, website, or telephone number, 
and they will be approached by a study staff member trained to provide the caller with information about 
the study and to schedule interested persons for an in -person interview. Participants will undergo an initial 
screening and those who pass the initial screen will undergo informed consent procedures.  
  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   12 To address retention, we will incorporate standard procedures used in previous Phase 1 trials, which 
include financi al compensation for study participation.  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
The study drug, IXT-m200 , is a chimeric mAb that binds METH with high affinity. The product contains 
a murine METH -binding variable region and the constant domains of a human IgG 2κ. This antibody 
isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. 
IXT-m200 specifically targets METH and does not rely on binding to any endogenous target for its 
action.  
  
6.1.2  DOSING AND ADMINISTRATION  
 
Participants  will only be randomized and dosed with study drug if they have passed all screening 
requirements before or on Day 1. Participants  will be randomized on Day 1  to receive 3 g IXT -m200 or 
placebo  (7:2). Each participant  will receive 1 dose of assigned study drug on Day 1 .   
 
Participants  should lie supine or semi -reclined during dose administration. Each dose will be given with 
an infusion pump over 30 minutes with a 50 -mL saline flush dispensed after each dose to ensure the entire 
dose is flushed through the infusion set.  The study drug  infusion start/stop time, infusion rate, infusion 
volume, whether the infusion was completed, if it was stopped, or stopped and restarted will be recorded.  
 
Participants  will be asked to eat a light meal prior to a rriving at the study  center but not have anything  but 
clear liquids  to eat or drink for 1 hour before appointment time . Participants  will be offered a light meal 
after dosing completion . 
 
All study drug doses will be administered in a blinded manner by the Investigator  or designee.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  ACQUISITION AND ACCOUNTABILITY  
 
Study Drug : All required IXT -m200 vials will be shipped  by Sponsor  to the study site prior to study 
initiation.  All unused supplies will be checked against the drug accountability records during the study 
and/or at the end of the study. All unused study drug must be disposed of in accordance with applicable 
requirements.   
  
Placebo: An unblinded member of th e site staff  will be responsible for acquiring commercially available 
normal saline for use as placebo for IXT -m200.  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
Study Drug : IXT -m200 is formulated as a  solution containing approximately 20 mg/mL IXT-m200 in 10 
mM sodium phosphate, pH 6.5, 150 mM sodium chloride, and 0.05% w/v polysorbate  80. The product is 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   13 a clear solution packaged in glass vials with stoppers and flip -off seals. Catalent Pharma Solutions 
manufactures the formulated active pharmac eutical ingredient.  
 
Labels will be similar to the following:  
  
InterveXion Therapeutics®  
Anti-methamphetamine IXT -m200  
18.5-21.5 mg/mL  
Manufactured: DD MMM YYYY  
DP Lot: XXXXXXX  
Catalent Lot: XXXXX  
10 mM sodium phosphate, 150 mM sodium chloride, pH 6.5, with 0.05% Tween 80  
Store refrigerated at 2 to 8°C  
CAUTION: New Drug – Limited by Federal (or United States) law to investigational use only.  
InterveXion Therapeutics, LLC  
4301 W. Markham, Slot 831, Little Rock, AR 72205  
 
Placebo: Normal saline (0.9% sodium chloride) should be a clear solution for injection. Packaging and 
labeling will be appropriate for use.  
 
Only unblinded study staff will have access to the labeled study drugs.    
 
6.2.3  PRODUCT STORAGE AND STABILITY  
 
IXT-m200 vials are single -use and shou ld be stored refrigerated at 2 to 8°C. The stability of the product is 
still under investigation and stability protocols will run concurrent to the study. A previous lot of 
IXT-m200 remained stable after 48 months of refrigerated storage when the stability protocol was 
terminated.  
 
6.2.4  PREPARATION  
 
An unblinded  staff member (e.g.,  pharmacist ) will prepare the study drugs for administration. The 
appropriate amount of IXT -m200 should be administered over 30 min .  Since IXT -m200 is a clear 
solution, it will appear similar to saline placebo . 
  
Placebo:  Normal saline requires no preparation prior to administration.  
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
 
Each potential participant  will be assigned a un ique number in the screening process (screening number). 
This number will be used to identify the participant  throughout the study.  
 
Participants  who qualify will be randomized  on Day 1 to 3 g IXT -m200 or placebo ( 7:2). 
 
Unblinding of treatment assignment during the study is discouraged and should occur only if it is 
absolutely necessary for the Investigator , Sponsor, or participant  to know what he or she received  for 
safety reasons . If the Sponsor  or the Investigator  deem s identification of the study drug to the participant  
as necessary for the purpose of providing urgent care, the pharmacy will inform the Investigator  of the 
assignment, who will notify the Sponsor and participant . The process of unblinding will be appropr iately 
documented in the Investigator  file. The date and reason for the unblinding must be recorded. When 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   14 possible, the Sponsor should be notified prior to unblinding; otherwise, they must be notified within 24 
hours after unblinding.  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
 
Study drug  is administered by intravenous infusion by qualified personnel  who are blinded to the 
treatment assignment of the participant . Compliance with dosing will be verified by reference to the CRF 
documentation of dosing.  
 
6.5 CONCOMITANT THERAPY  
 
All concomitant medications (i .e., prescription medications, over -the-counter medications, 
non-prescription medications , and supplements ) taken during study participation will be recorded on the 
CRF. For this protocol, a prescription me dication is defined as a medication that can be prescribed only 
by a properly authorized/licensed clinician.  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
 
The criteria outlined in section 8.2.3.1  will be used to categorize the severity of all AEs. The Sponsor, in 
consultation with the Investigator, will  suspend enrollment until a full safety review is performed if any 1 
of the following events occurs, unless the event was clearly unrelated to study drug administration:  
 
• Two (2 ) participants experience a Grade 3 AE ; or, 
• One (1) participant experiences a Grade 4 AE ; or, 
• A death occurs.  
 
Events unrelated to study drug administration include those that are temporally unrelated to study drug  
administration, such as events occurring prior to dosing; or events in which the participant  is a passiv e 
victim, such as a passenger in a motor vehicle crash.  
 
A decision to reinitiate enrollment will be made by the Sponsor following any necessary consultation with 
the appropriate authorities based on the results of the safety review.  All other study proced ures will 
continue per protocol  during any study pause.  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participants  who withdraw consent for future study visits (following early termination assessments) will 
be considered ‘withdrawn’. Participants are free to withdraw at any time upon request ; they will be asked 
to complete early termination assessments as soon as possible . 
 
Participants  that receive less than the complete single dose of study drug but agree to continue 
participation in other study procedures and assessments will be considered ‘discontinued’. Participants are 
free to discontinue at any time during dosing upon request. Participants  will be encouraged to complete 
study visits  and assessments, even if they elect to discontinue study drug administration. In this case, all 
study activities will be completed per protocol with the exception of dose administration .  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   15  
The I nvestigator may discontinue a participant from study drug administration for the following reasons : 
• the participant  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation, such as an infusion reaction , 
• any clinical AE, laboratory abnormality, or other medical condition or situation occurs such that 
continued participation in the study would not be in the best interest of the participant ,  
• significant non -compliance by the participant , 
• if, in the  Investigator’s  opinion, continuation with study drug administration would be detrimental to 
the participant ’s well -being,   
• at the specific request of InterveXion (Sponsor) or the Investigator .  
 
In all cases, the reason for withdrawal or discontinuation must be recorded in the  CRF and in the 
participant ’s medical records. If the reason is not known, an attempt must be made to follow up with the 
participant  to establish whether the reason was an AE, and, if so, this AE must be reported . Once the 
participant  has been contacted and expresses their decision to withdraw from further participation in the 
study, the research staff will cease to try to make further contact.  
 
Participant s who withdraw or are discontinued  may be replaced at Sponsors discretion until there are 6 
participants who have completed the p rotocol through Day 63 . 
 
7.3 LOST TO FOLLOW -UP 
 
A participant will be considered lost to follow -up if he or she fails to return for  the final scheduled visit , 
including an early term visit, and is unable to be contacted by the study site  staff.  
 
The following actions must be taken if a participant fails to return to the clinic for a required study visit:  
• The site will attempt to contact the participant and reschedule the missed visit , counsel the 
participant on the importance of maintaining the assign ed visit schedule , and ascertain if the 
participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the Investigator or designee will make every 
effort to regain contact with the participant (where possible,  3 telephone calls and, if necessary, a 
certified letter to the participant’s last known mailing address or local equivalent methods). These 
contact attempts should be documented in the participant’s medical record or study file.  
• Should the participant  continue to be unreachable, he or she will be considered to have withdrawn 
from the study with a primary reason o f lost to follow -up. 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 SAFETY AND OTHER ASSESSMENTS  
 
Assessments are to be performed at the time points described in the Schedule of Activities  (1.3).  
 
8.1.1  ELIGIBILITY CRITERIA  
 
• Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM -5) criteria checklist 
should be used to assess participants  for Substance Use Disorders (including METH, opioids, 
alcohol, nicotine, marijuana, etc.)  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   16 • Urine drug screen to include  illicit substances (barbiturates, benzodiazepines, cocaine, opiates, 
phencyclidine, MDMA, METH, or amphetamine) on Day 1  (a positive test for 
tetrahydrocannabinol may be acceptable if the subject is not intoxicated at the discretion of the 
Investigator).  
 
8.1.2  MEDIC AL AND MEDICATION HISTORY  
 
• A complete medical history will be obtained by interview and any available medical records  at 
screening . Interim medical history will be obtained at all subsequent time points.  
• A complete medication history will be obtained by interview and any available medical records  at 
screening , with particular attention to any medications taken in the previous 12  months. The 
medication history, including concomitant medications , will be updated at all subsequent visits.  
 
8.1.3  VITAL SIGNS  
 
• Vital sign measurements (heart rate, blood pressures [systolic and diastolic], respiratory rate, 
temperature [oral], and pulse oximetry readings) will be obtained after the participant has been 
resting for at least 5 minutes.  
 
8.1.4  PHYSICAL EXAM  
 
• Physical exami nation (excluding rectal/genital and breast examination) will consist of an 
examination of the following: general appearance, neurological, skin, head, eyes, ears, nose, throat, 
neck, lymph nodes, chest, heart, abdomen, and extremities.  
• Targeted  physical exams will include heart, lungs, abdomen, skin, and site of injection. Additional 
areas may be targeted if AEs or other complaints require appropriate and more detailed exams.  
• Height and weight will be recorded  at screening; weight will be record ed at subsequent visits . 
 
8.1.5  PSYCHIATRIC EVALUATION  
 
• A psychiatric history will be obtained at screening evaluating for (but not limited to) the following: 
major current depression, psychosis, bipolar illness, organic brain disorder, anorexia nervosa or 
bulim ia disorder or dementia, which require ongoing medication or which would make study 
compliance difficult in the opinion of the Investigator.  
 
8.1.6  PREGNANCY TEST  
 
• Urine pregnancy tests will be performed on all females at designated visits.  
 
8.1.7  LABORATORY TESTS  
 
The below laboratory tests will be centrally assessed:  
• Hematology  
o Erythrocytes: red blood cell (RBC) count, hematocrit, hemoglobin, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, red cell  
distribution width, and reticulocyte count as an absolute value.  
o Leukocytes: WBC and differential (basophils, eosinophils, lymphocytes, monocytes, and 
neutrophils) reported as absolute values.  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   17 o Coagulation: platelet count, prothrombin time measured as inte rnational normalized ratio, 
activated partial thromboplastin time.  
• Serum Chemistry  
o Liver: alkaline phosphatase, ALT, AST (serum glutamic -oxaloacetic transaminase), bilirubin 
(total, direct, and indirect), gamma -glutamyl transferase, and lactic dehydrogenas e. 
o Renal: blood urea nitrogen, creatinine, and uric acid.  
o Electrolytes, sodium, potassium, chloride, and carbon dioxide.  
o General: CPK, albumin, calcium, magnesium, glucose (fasting), phosphate, protein (total), 
amylase, and lipase.  
• Urinalysis  
o Microscopic: pH, specific gravity, glucose, ketones, leukocyte esterase, nitrites, occult blood, 
and protein, RBCs/hpf, WBCs/hpf, bacteria, casts, epithelial cells, mucous threads, and 
crystals.  
o Quantitative: protein and creatinine if microscopic is positive for protei n. 
 
8.1.8  ELECTROCARDIOGRAMS  
 
• Electrocardiograms (12 -lead) will be recorded after the participants  have been supine for 5 min utes. 
Standard ECG parameters including heart rate, QRS, PR, QT, and QTc intervals will be measured. 
The ECGs will be read by a study physician to assess for any abnormalities. Abnormal ECG 
parameters include, but are not limited to ventricular hypertrophy, le ft axis deviation, atrial or 
ventricular arrhythmias other than sinus, and prolonged QTc (greater than 500 ms). ECGs may be 
repeated if data quality is compromised due to poor lead placement or machine error.  
• Confirmed ECG anomalies will be referred for a ppropriate medical follow -up. 
 
8.1.9  BLOOD FOR PK/HACA  AND CYTOKINES  
 
• PK of IXT -m200 : A validated enzyme linked immunosorbent assay procedure will be used to 
quantitate IXT -m200 in serum samples. Approximately 1 mL per sample is required.  
• HACA:  A validated elect rochemiluminescent procedure has been developed to  quantitate HACA in 
serum samples. Approximately 1 mL per sample is required.  These samples may be analyzed after 
the completion of this study.  
• Cytokine panel to include at a minimum IL-6, IL -8, and TNFα levels will be determined only if any 
study drug  infusion reaction occurs.  
 
8.2 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.2.1  DEFINITIO N OF ADVERSE EVENTS (AE)  
 
An AE is any untoward medical occurrence in a person  administered study drug , whether or not 
considered intervention -related . An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug , 
whether or not related to the IXT-m200  dose.   
 
The AE may be:  
• a new illness;  
• worsening of a sign or symptom of the condition under treatment or of a concomitant illness;  
• an effect of the study medication, including comparator; or  
• a combination of 2 or more of these factors.  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   18  
No causal relationship with IXT -m200 or with the clinical  study itself is implied by the use of the term 
“AE”. Pre -existing conditions will not be reported as an AE unless there has been a substantial increase in 
the severity or frequency of the problem which has not been attributed to natural history.  
 
Surgical  procedures themselves are not AEs; they are therapeutic measures for conditions that require 
surgery. The condition for which the surgery is required may be an AE. Planned surgical measures 
permitted by the clinical study protocol and the condition(s) lea ding to these measures are not AEs.  
 
Adverse events fall into the categories “nonserious” or “serious”.  
 
8.2.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An SAE is an AE that at any dose:  
 
• results in death;  
• is life -threatening;  
• requires hospitalization or prol ongation of existing hospitalization;  
• results in persistent or significant disability/incapacity; or  
• is a congenital anomaly/birth defect.  
 
The term “life -threatening” in the definition of “serious” refers to an event in which the person  was at 
immediate risk of death at the time of the SAE; it does not refer to an SAE which hypothetically might 
have caused death if it were more severe.  
 
Medical and scientific judgment will be exercised in deciding whether other AEs, such as important 
medical events that m ay not be immediately life -threatening or result in death or hospitalization but may 
jeopardize the person  or may require intervention to prevent one of the other outcomes listed above. 
These will also usually be considered serious.  
 
8.2.3  CLASSIFICATION OF AN ADVERSE E VENT  
8.2.3.1  SEVERITY OF EVENT  
 
The general approach outlined by the Club Phase 1 working group in the British Journal of Clinical 
Pharmacology2 will be used to categorize the severity of all AEs. The stopping rules outlined in Sect ion 
7.1 will apply.  
 
The following criteria will be used:  
• Grade 1: Transient or mild discomfort; does not interfere with daily activity; no medical 
intervention/treatment required,  
• Grade 2: Mild to  moderate limitation in activity, some assistance may be needed; no or minimal 
intervention/treatment required, including but not limited to mild analgesics, antacids or 
antibiotics,  
• Grade 3: Marked limitation in activity, some assistance usually required ; medical 
intervention/treatment required,  
• Grade 4: Extreme limitation in activity, significant assistance required; significant medical 
intervention/treatment, likely requiring hospitalization.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   19 For example, i f hypotension is not immediately responsive to medications, this will constitute a Grade 3 
reaction and it will be documented as such. Similarly, if bronchospasm (SaO2 < 93% on oxygen) occurs 
and requires medications, this will constitute a Grade 3 reaction, and will be documented as such.  
 
8.2.3.2  RELATIONSHIP TO STUDY INTERVENTION  
 
All adverse events (AEs) must have their relationship to study intervention assessed by the clinician who 
examines and evaluates the participant based on temporal relationship and his/her clinical judgment. The 
degree of  certainty about causality will be graded using the categories below. In a clinical trial, the study 
product must always be suspect.  
 
DEFINITELY  – The AE:  
• is clearly related to the investigational agent or research intervention;  
• has a temporal relationship to the administration of the study drug;  
• follows a known pattern of response;  
• occurs in the absence of an alternative cause.  
 
PROBABLY – The AE:  
• follows a reasonable temporal sequence from study drug administration;  
• abates upon discontinuation of the drug;  
• cannot be reasonably explained by the known characteristics of the participant ’s clinical state.  
 
POSSIBLY – The AE:  
• follows a reasonable tempor al sequence from study drug administration;  
• could have been produced by the participant ’s clinical state or by other modes of therapy 
administered to the participant .  
 
UNLIKELY – The AE:  
• does not follow a reasonable temporal sequence from study drug adm inistration;  
• is readily explained by the participant ’s clinical state or by other modes of therapy administered 
to the participant .  
 
UNRELATED – The AE:  
• is definitely produced by the participant ’s clinical state or by other modes of therapy administered 
to the participant .  
 
8.2.3.3  EXPECTEDNESS  
 
The Sponsor will be responsible for determining whether an AE is expected or unexpected. An AE will be 
considered unexpected if the nature, severity, or freque ncy of the event is not consistent with the risk 
information previously described for the study agent.  
 
8.2.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -
UP 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, during engagement of the participant with 
the smartphone app, or upon review by a Study Monit or. All AEs including local and systemic reactions 
not meeting the criteria for SAEs will be captured on the appropriate CRF. Information to be collected 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   20 includes event description, time of onset, clinician’s assessment of severity, relationship to study p roduct 
(assessed only by those with the training and authority to make a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately 
regardless of relationship. All AEs will be followed t o adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time 
during the study, i t will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity. All AEs characterized as intermittent require documentation of onset and 
duration of each epis ode.  
 
The Investigator  will record all reportable events with start dates occurring any time after informed 
consent is obtained until the last day of study participation. At each study visit, the Investigator will 
inquire about the occurrence of AE/SAEs since the last visit. Ev ents will be followed for outcome 
information until resolution or stabilization.  
 
8.2.5  ADVERSE EVENT REPORTING  
 
All AEs (whether serious or nonserious) that occur after the participant  has been randomized into a 
treatment group must be documented on the approp riate pages of the CRF. For all AEs, the Investigator  
will provide an assessment of the AE, its treatment and resolution, and its relationship to IXT -m200. 
Every attempt should be made to describe the AE in terms of a diagnosis. If appropriate, component 
symptoms should also be listed below the diagnosis. If only nonspecific signs or symptoms are present, 
then these should be recorded as a diagnosis.  
 
All participants  who have AEs, whether considered associated with the use of IXT -m200 or not, will be 
monit ored to determine the outcome. The clinical course of the AE will be followed up according to 
accepted standards of medical practice, even after the end of the period of observation  to a maximum of 
30 days  following the end of study visit . Should the AE re sult in death, a full pathologist’s report should 
be supplied, if possible.  
 
8.2.6  SERIOUS ADVERSE EVENT REPORTING  
 
The Investigator  will complete an SAE form within the following timelines:  
• All deaths and immediately life -threatening events, whether related o r unrelated, will be recorded 
on the designated SAE form and submitted to the Sponsor within 24 hours of site awareness.  
• Other SAEs regardless of relationship, will be submitted to the Sponsor within 72 hours of site 
awareness.  
 
All SAEs will be followed until satisfactory resolution or until the site Investigator deems the event to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested by 
the Sponsor and should be provided as soon a s possible.  
 
Information not available at the time of the initial report will be documented on a follow -up SAE form. 
SAE information previously sent to the Sponsor will not be duplicated. When a nonserious event becomes 
serious, details will be forwarded immediately to the Sponsor on the designated SAE report form.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   21 The study Sponsor will be responsible for notifying the Food and Drug Administration (FDA) of any 
unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in no case later 
than 7 calendar days after the sponsor's initial receipt of the  information.  In addition, the Sponsor must 
notify FDA and all participating Investigators in an Investigational New Drug (IND) safety report of 
potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later 
than 15 calendar days after the sponsor determines that the information qualifies for reporting.  
 
The NIDA Project Officer (PO) will be notified by the Sponsor within 72 hours of the SAE occurrence, 
and also via NIDA’s online Serious Adverse Event Tracking and Reporting System (SAETRS).  
 
8.2.7  REPORTING EVENTS TO PARTICIPANTS  
 
It is not anticipated that safety updates, including AEs or SAEs, will be reported to study participants . 
 
8.2.8  EVENTS OF SPECIAL INTEREST  
 
Not applicable.  
 
8.2.9  REPORTING OF PREGNANCY  
 
If a participant  is found to be pregnant after they have received study drug , they should complete the 
study, with no further study drug  doses administered, and be followed to determine the outcome of the 
pregnancy if the participant  is willing. Generally, foll ow-up will be no longer than 6 to 8 weeks after the 
estimated delivery date. While pregnancy itself is not considered an AE or SAE, any pregnancy 
complications will be recorded as an AE or SAE.  
 
Pregnancies should be reported by the Investigator to the Spo nsor within 2 days of identification.  
 
8.3 UNANTICIPATED PROBLEMS  
 
8.3.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
Unanticipated problems involving risks to participants or others will include, in general, any incident, 
experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedur es that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the participant population being 
studied;  
• Related or possibly related to participation in the  research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places participants or others at a greater ris k of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.3.2   UNANTICIPATED PROBLEM REPORTING  
 
Investigators will adhere to the following guidelines for prompt reporting:  
• Unanticipated problems that are SAEs should be reported to the IRB within 1 week of the 
Investigator becoming aware of the event.  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   22 • Any other unanticipated problem should be reported to the IRB within 2 weeks of the Investigator 
becoming aware of the problem . 
 
All unanticipated problems should be reported by the Sponsor to the supporting Department of Health and 
Human Services (DHHS) agency head (or designee), and Office for Human Research Protections (OHRP) 
within one month of the IRB’s receipt of the report  of the problem from the Investigator.  
 
In some cases, the requirement for prompt reporting may be met by submitting a preliminary report to the 
IRB, the supporting DHHS agency head (or designee), and OHRP, with a follow -up report submitted at a 
later date  when more information is available.  Determining the appropriate time frame for reporting a 
particular unanticipated problem requires careful judgment by persons knowledgeable about human 
participant  protections.  The primary consideration in making these  judgments is the need to take timely 
action to prevent avoidable harms to other participants.  
 
8.3.3  REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
 
It is not expected that unanticipated problems will be reported to study participants, although appropriate 
study-related actions may be undertaken if determined necessary.  
 
9 STATISTICAL CONSIDERATIONS   
 
A statistical analysis plan (SAP) will be prepared after the protocol is approved. This document will 
provide further details regarding the definition of analysis variables and analysis methodology to address 
all study objectives. The SAP will serve as a complement to the protocol and supersedes it in case of 
differences.  
 
9.1 STATISTICAL HYPOTHESES  
 
This is primarily a PK and safety study that is not evaluatin g any formal hypotheses.  
 
Primary:  
1) To evaluate the safety and tolerability of a single 3 -g intravenous dose of IXT -m200 in healthy 
participants.  
 
Secondary:  
1) To characterize the pharmacokinetics of IXT -m200 following a single 3 -g intravenous dose of I XT-
m200 in healthy participants.  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
The sample size chosen for this study is not based on statistical considerations. The number of subjects 
within each dose group was chosen based on historical experience with safety and tolerance  trials  and to 
match the study design used in the previous Phase 1 study with IXT -m200 which provided adequate 
safety and pharmacokinetic data . The sample size falls within the range of those used in other studies of 
this nature.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   23 9.3 POPULATIONS FOR ANALYSES  
 
The study analysis populations will consist of:  
 
Population  Description  
Pharmacokinetic  All participants who receive study drug and have at least one measured IXT -m200 
concentration at a scheduled PK time point after start of dosing . If participants do 
not receive a complete dose or have incomplete data, a decision will be made on a 
case-by-case basis as to their inclusion in the analysis. This population will be used 
for all PK summaries.  
Safety  All participants who receive at least  a dose of study drug, including placebo. This 
population will be used for all demographic and safety summaries.  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 
Safety  and tolerability  results will be summarized using descriptive statistics. Continuous variables will 
be summarized using appropriate summary statistics (e.g., the number of non -missing observations (n), 
mean, standard deviation, median, 25th and 75th percentiles, minimum, and maximum; geometric mean, 
coefficient of variation (CV%), and 95% CIs may also be presented , as appropriate). Categorical variables 
will be summarized with the frequency count and percentage of participant s with non -missing data.  
 
The results of this study will be reported using summary tables, figures, and data listings. All summaries 
will be by treatment group.  
 
9.4.2  SAFETY ANALYSES  
 
All safety analyses will be performed on the  Safety population.  Descriptive statistics will be used to 
summarize AEs, serious AEs, AEs causing withdrawal  or discontinuation  from the study, AEs judged by 
the Investigator as potentially related to study drug,  changes in laboratory and vital signs , and immune 
response by measurement of anti-IXT-m200 antibody levels . AEs will be tabulated by  Medical Dictionary 
for Regulatory Activities (MedDRA)  system organ class (SOC) and preferred term .  
 
9.4.3  BASELINE DESCRIPTIVE STATISTICS  
 
Demographic and baseline characteristics (age, sex, race, ethnicit y, body weight, height, and BMI) will be 
summarized by treatment group using descriptive statistics for the Safety  population.  
 
9.4.4  TABULATION OF INDIVIDUAL PARTICIPANT DATA  
 
Participant -level listings will include collected data by treatment group and timepoint.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   24 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PROCESS  
 
10.1.1.1  CONSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
 
Consent forms describing in detail the study intervention, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting the screening 
process, and subsequently administering study inte rvention. Other information may be provided to 
potential participants to help describe the nature and objectives of the study and clinical research in 
general, including access to web -based material  describing the study. All such participant -facing 
informa tion will be approved in advance by the study’s IRB.  
  
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study part icipation. Extensive discussion of risks and possible 
benefits of participation will be provided to the participants. Consent forms will be IRB -approved and the 
participant will be asked to read and review the document. The Investigator or designee will ex plain the 
research study to the participant and answer any questions that may arise. All participants will receive a 
verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks 
of the study and of their rights  as research participants. Participants will have the opportunity to carefully 
review the written consent form and ask questions prior to signing. The participants should have the 
opportunity to discuss the study with advisors  or think about it prior to ag reeing to participate. The 
participant will sign the Informed Consent Form ( ICF) prior to any procedures being done specifically for 
the study. The participants may withdraw consent at any time throughout the course of the trial. A copy of 
the ICF will be given to the participants for their records. The rights and welfare of the participants will 
be protected by emphasizing to them that the quality of their medical care will not be adversely affected if 
they decline to participate in this study.  
 
10.1.2  STUDY DISC ONTINUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated at the sole discretion of the Sponsor. 
Written notification, documenting the reason for study suspension or termination, will be provided by the 
Sponsor to Investiga tors, NIDA, and, if necessary, FDA. Investigators will notify participants and the 
IRB. Sponsor will provide the reason(s) for the termination or suspension. Participants will be contacted, 
as applicable, and informed of changes to the study visit schedule . 
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants either related to the 
study intervention or unrelated events (such as a national he alth emergency);  
• Demonstration of efficacy that would warrant early termination;  
• Insufficient compliance to protocol requirements;  
• Data that are not sufficiently complete and/or evaluable;  
• Determination that the primary endpoint has been met;  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   25 • Determination of futility.  
 
At the discretion of the Sponsor, if temporarily suspended, the Study may resume once any relevant 
concerns have been addressed.  
 
10.1.3  CONFIDENTIALITY AND PRIVACY  
 
Participant confidentiality is held strictly in trust by the participating Investigators, their staff, and the 
Sponsor and their agents. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relatin g to participants. All personal details of participants will be 
treated as confidential by the Investigator and staff, and handling of personal data will be in compliance 
with the Health Insurance Portability and Accountability Act of 1996 and any applicab le state laws 
governing the individual study sites. The study participants ’ contact information will be securely stored at 
each clinical site for internal use during the study. At the end of the study, all records will continue to be 
kept in a secure locat ion for as long a period as dictated by the reviewing IRB, institutional policies, or 
Sponsor requirements.  
  
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the stud y or the data will be released to any unauthorized third 
party without prior written approval from the Sponsor. The Study Monitor or other authorized 
representatives of the Sponsor, IRB or regulatory agencies may inspect any documents maintained by the 
Investigator, such as available medical records (office, clinic, or hospital) and pharmacy records for the 
participant s in this study. The clinical study site will permit access to such records.  
  
Certificate of Confidentiality  (COC) : To further protect the p rivacy of study participants, a COC is 
granted by the National Institutes of Health ( NIH) to all awardees conducting research that collects or 
uses identifiable, sensitive information. This certificate protects identifiable research information from 
forced  disclosure. It allows the Investigator and others who have access to research records to refuse to 
disclose identifying information on research participation in any civil, criminal, administrative, 
legislative, or other proceeding, whether at the federal,  state, or local level. By protecting researchers and 
institutions from being compelled to disclose information that would identify research participants, 
Certificates of Confidentiality help achieve the research objectives and promote participation in stu dies by 
helping assure confidentiality and privacy to participants.  
 
10.1.4  FUTURE USE OF STORED SPECIMENS AND DATA  
 
Data collected for this study will be analyzed and stored as described above. After the study is completed , 
the de -identified, archived data will be maintained as long as regulations require, and will be made 
available by the Sponsor for use by other researchers including those outside of the study via a data 
sharing agreement.   
 
Blood and urine specimens remaining after clinical safety assessm ents are performed will be stored only 
until the clinical study report is completed.  
  
Blood specimens remaining after PK assessments are performed will be stored for at least 12 months for 
future drug metabolism and PK analysis if needed.  
 
No genetic analysis will be performed.  
 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   26 10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
 
Sponsor Contact  Principal Investigator  
W. Brooks Gentry, MD  Magdy L Shenouda, MD  
InterveXion Therapeutics, LLC  Clinilabs  
4301 W. Markham St. #831  
Little Rock, AR 72205  4 Industrial Way West, 2nd Floor  
Eatontown, NJ 07724  
501-320-7601  212-994-4569  
gentrywilliamb@uams.edu  mshenouda@clinilabs.com  
 
10.1.6  SAFETY OVERSIGHT  
 
As a Phase 1 study specifically designed to determine safety of a single 3 -g dose of IXT -m200, robust 
evaluation of safety parameters and safety oversight will be conducted. The clinical site has been selected 
based on its track record as a Phase 1 safety unit, with all available resources for detection and 
management of any observed adverse events during the study. The Investigator will directly monitor 
participant safety and make real -time recommendations for any necessary interventions or study 
modificat ions to the Sponsor’s Medical Liaison.  
 
10.1.7  CLINICAL MONITORING  
 
Clinical site monitoring is conducted to ensure that the rights and well -being of study participants are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of the 
trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable 
regulatory requirement(s).  
  
Data at clinical sites will be monitored by one or more Study Monitors. Throughout the course of th e 
study, the Study Monitor will make frequent contact with the Investigator. This will include telephone 
calls and on -site visits. During the on -site visits, the Study Monitor will perform source data verification 
(a comparison of the data in the electroni c data capture systems with the participant’s medical records 
including verification of informed consent). This will require direct access to all original records for each 
participant (e.g., clinic charts).  
 
The Study Monitor will also perform drug account ability checks and will request to perform a review of 
the Investigator’s  study file to assure completeness of documentation in all respects of clinical study 
conduct.  
  
Upon completion of the study, the Study Monitor will arrange for a final review of the  study files, after 
which the files should be secured for the appropriate time period. The Investigator, or appointed delegate, 
will meet with the Study Monitor during the on -site visits and will cooperate in providing the documents 
for inspection and resp onding to inquiries. In addition, the Investigator will permit inspection of the study 
files by authorized representatives of the Sponsor or regulatory agencies.  
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
 
The clinical site will perform internal quality manage ment of study conduct, data and biological specimen 
collection, documentation, and completion. Quality control (QC) procedures will be implemented 
beginning with the data entry system and data QC checks that will be run on the database will be 
generated. A ny missing data or data anomalies will be communicated to the site(s) for clarification  and 
resolution.  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   27  
Following written Standard Operating Procedures (SOPs), the Study Monitor will verify that the clinical 
trial is conducted and data are generated and b iological specimens are collected, documented (recorded), 
and reported in compliance with the protocol, GCP, and other applicable regulatory requirements.  
 
The investigational site will provide direct access to all source data/documents and reports for th e purpose 
of monitoring and auditing by the Sponsor, and inspection by local and regulatory authorities.  
 
10.1.9  DATA  HANDLING  AND RECORD  KEEPING   
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at each site under the supervision of the site 
Investigator. The Investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported. All sou rce documents should be completed in a neat, legible manner to 
ensure accurate interpretation of data.   
 
Data recorded in the CRF(s) derived from source documents should be consistent with the data recorded 
on the source documents. Hardcopies of any sourc e document(s) used for recording data for each 
participant enrolled in the study will be filed at the investigative site to be reviewed by the Study Monitor 
for accuracy.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactio ns data) and clinical 
laboratory data will be entered into a 21 CFR Part 11 -compliant data capture system. The data system 
includes password protection and internal quality checks, such as automatic range checks, to identify data 
that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source 
documents.  
 
10.1.9.2  STUDY RECORDS RETENTION  
 
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 
application in an ICH region and unti l there are no pending or contemplated marketing applications in an 
ICH region, or until at least 2 years have elapsed since the formal discontinuation of clinical development 
of the investigational product. These documents should be retained for a longer period, however, if 
required by local regulations. No records will be destroyed without the written consent of the Sponsor, if 
applicable. It is the responsibility of the Sponsor to inform the Investigator when these documents no 
longer need to be retained .  
 
The following records must be retained by the Investigator :  
• Signed ICFs for all participant s 
• Screening log (if applicable), and enrollment log  
• Record of official communications between the site and the IRB  
• Composition of the IRB or other applicable statement  
• Record of all significant communications between the site and Sponsor  
• List of sub-Investigators and other appropriately qualified persons to whom the Investigator  has 
delegated significant trial -related duties, together with their roles in the study and their signatures  
• Copies of CRFs and of documentation of corrections for all participa nts 
• Drug accountability records  
• Record of any body fluids or tissue samples retained  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   28 • All other source documents ( medical  records, hospital record copies, laboratory records, etc)  
• All other documents as listed in Section 8 of the ICH consolidated guideline on GCP (Essential 
Documents for the Conduct of a Clinical Trial)  
 
If the Investigator  is unable to continue to store the study records, s/he must contact the Sponsor to make 
alternative arrangements. Details of these arrangements should be documented.  
 
10.1.10  PRO TOCOL DEVIATIONS  
  
A protocol deviation is any change, divergence, or departure from the study design or procedures defined 
in the protocol; or any noncompliance with the clinical trial protocol, GCP, or manual of procedures 
requirements. The noncomplianc e may be either on the part of the participant, an Investigator, or study 
site staff. As a result of deviations, corrective actions are to be developed by the site and implemented 
promptly. All deviations will be compiled in a centralized location.  
  
These  practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, Section 5.1.1  
• 5.20 Noncompliance, Sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site to use con tinuous vigilance to identify and report deviations in a timely  
manner. The Investigator will document and explain any deviation from the approved protocol in the  
study source documents and notify the Sponsor. Protocol deviations may need to be sent to the  reviewing  
IRB, depending on the nature of the deviation and the IRB guidelines. The Investigators and study staff  
are responsible for knowing and adhering to the IRB requirements.  
 
Deviations will be classified by whether or not they meet the definition of important protocol deviations. 
Important protocol deviations are a subset of deviations that might significantly affect the completeness, 
accuracy, and/or reliability of the study data or that might significantly affect a participant 's rights, safety, 
or well -being. Deviations will be categorized by type and will be reviewed on an ongoing basis.  
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the 
published results of NIH -funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptanc e for 
publication.  
  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission rule. As such, this trial will be registered at www. clinical trials.gov, and results information 
from this trial will be submitted to www. clinical trials.gov. In addition, every attempt will be made to 
publish results in peer -reviewed journals.   
 
10.1.12  CONFLICT OF  INTEREST  POLICY  
 
Any conflict of  interest of persons who have a role in the design,  conduct, analysis, publication, or any 
aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of 
interest will be required to have such conflicts managed in  a way that is appropriate to their participation 
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   29 in the trial. The Sponsor has established policies and procedures to disclose all conflicts of interest and 
will establish a mechanism for the management of all reported dualities of interest.  
 
10.2 ABBREVIATION S 
 
AE Adverse Event  
ALT  Alanine Aminotransferase  
AST  Aspartate Aminotransferase  
BMI  Body Mass Index  
CFR  Code of Federal Regulations  
CI Confidence Interval  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CPK  Creatine Phosphokinase  
CRF  Case Report Form  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Coefficient of Variation  
DHHS  Department of Health and Human Services  
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition  
ECG  Electrocardiogram  
ET Early termination visit  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
HACA  Human Anti -Chimeric Antibodies  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
ICF Informed Consent Form  
IgG Immunoglobulin G  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
METH  Methamphetamine  
MDA  Methylenedioxyamphetamine  
MDMA  MethylenedioxyMETH  
NIH  National Institutes of Health  
NIDA  National Institute on Drug Abuse  
NOAEL  No Observed Adverse Effect Level  
OHRP  Office for Human Research Protections  
PK Pharmacokinetics  
PO Program Officer  
QC Quality Control  
RBC  Red Blood Cell  
SAE  Serious Adverse Event  
SAETRS  Serious Adverse Event Tracking and Reporting System  
SAP Statistical Analysis Plan  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   30 SOC  System Organ Class  
SOP Standard Operating Procedure  
STAMPOUT  Study of Antibody for Methamphetamine Outpatient Therapy  
UP Unanticipated Problem  
US United States  
Vd Volume of Distribution  
WBC  White Blood Cell  
 
 
10.3 PROTOCOL  AMENDMENT  HISTORY  
 
Version  - Date  Description of Change  Brief Rationale  
1 - 25 Aug 2021  Not applicable  New protocol  
 
 
 
  
Phase 1 Safety, Tolerability, and Pharmacokinetics of IXT -m200  in Healthy Volunteer s Version 1 
M200C -2102 25 Aug 2021  
 
   31 11 REFERENCES  
 
1. Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric 
anti-methamphetamine monoclonal antibody in healthy volunteers. mAbs 2014; 6:1649 –56. 
2. Sibille M, Patat A, Caplain H, Donazzolo  Y. A safety grading scale to support dose escalation 
and define stopping rules for healthy subject first -entry -into-man studies. Br J Clin Pharmacol 
2010; 70:736 –48. 
  
 